Related Experiment Video

Updated: Jul 13, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Controversies in the treatment of pneumococcal community-acquired pneumonia

Charles Feldman1, Ronald Anderson

  • 1University of the Witwatersrand Medical School, Division of Pulmonology, Department of Medicine, Parktown, Johannesburg, South Africa. feldmanc@medicine.wits.ac.za

Future Microbiology
|July 31, 2007
PubMed

Insights

Community-acquired pneumonia (CAP) is a major global health threat. Research focuses on antibiotic resistance and adjunctive therapies to improve treatment outcomes for CAP, especially Streptococcus pneumoniae infections.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pulmonology

Background:

  • Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality worldwide.
  • Increasing antimicrobial resistance among common CAP pathogens complicates treatment.
  • Despite available antibiotics, effective management remains challenging.

Purpose of the Study:

  • To review current research on optimal treatment strategies for CAP.
  • To evaluate the impact of antibiotic resistance and drug selection on CAP outcomes.
  • To explore adjunctive therapies that may improve CAP patient prognosis.

Main Methods:

  • Literature review of recent research in community-acquired pneumonia.
  • Analysis of studies focusing on antibiotic resistance patterns.
  • Examination of clinical trials for adjunctive therapies.

Main Results:

  • Antibiotic resistance is a growing concern in CAP management.
  • Optimal antibiotic choices and treatment regimens are still debated.
  • Adjunctive therapies show potential but require further investigation.

Conclusions:

  • Effective management of CAP requires addressing antibiotic resistance.
  • Further research is needed to establish definitive treatment guidelines and adjunctive therapies.
  • Strengthening strategies against Streptococcus pneumoniae is crucial.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...